Summary

Global Chronic Heart Failure Market, Analysis and Forecast: 2025-2035

Chronic heart failure is a long-term condition where the heart is unable to pump blood efficiently to meet the body's needs for oxygen and nutrients. This inability to pump effectively leads to fluid buildup in the lungs, abdomen, and legs, causing symptoms such as shortness of breath, fatigue, swelling, and exercise intolerance. chronic heart failure can develop because of underlying conditions such as coronary artery disease, hypertension, diabetes, or previous heart attacks. The condition can be classified into two main types based on heart function: Heart Failure with Reduced Ejection Fraction (HFrEF), where the heart’s pumping ability is weakened, and Heart Failure with Preserved Ejection Fraction (HFpEF), where the heart muscle becomes stiff and doesn't fill properly. Chronic heart failure is progressive, meaning it worsens over time, and requires ongoing management with medications, lifestyle changes, and sometimes medical devices or surgeries to improve symptoms and quality of life.

One of the key drivers of the chronic heart failure market is the rising prevalence of cardiovascular diseases such as hypertension, coronary artery disease, diabetes, and obesity. As these conditions become more widespread, the incidence of chronic heart failure increases, driving demand for effective treatments. The aging population is also contributing significantly to the growing market, as older individuals are at higher risk for developing heart failure. Additionally, advancements in diagnostic technologies and treatment options are allowing for earlier detection and more effective management of chronic heart failure, further boosting the market. The development of new, innovative therapies and medical devices, such as SGLT2 inhibitors and implantable devices, is improving patient outcomes, which in turn is accelerating the demand for chronic heart failure treatments. As more individuals are diagnosed and live longer with heart failure, the need for better treatment and management options continues to expand, propelling chronic heart failure market growth.

Despite the growth of the chronic heart failure market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of treatment. The development of advanced therapies, including new drug classes, medical devices, and hospitalization costs, can be prohibitively expensive, making it difficult for some patients to access the necessary care. This is especially true in low-income and emerging markets, where healthcare infrastructure may be limited.

Another significant challenge is the complexity of treatment. chronic heart failure is a multifactorial disease with various underlying causes, and patients often present with comorbidities such as diabetes, hypertension, and kidney disease. This makes it difficult to develop a one-size-fits-all treatment approach, and managing the disease often requires a combination of pharmacological and non-pharmacological interventions. Moreover, the long-term nature of the condition means that adherence to complex treatment regimens is often low, leading to poor outcomes and increased hospitalizations.

Additionally, while new drug therapies have shown promise, there is still a lack of effective treatments for certain subsets of patients, particularly those with heart failure with preserved ejection fraction (HFpEF). This group of patients has limited treatment options compared to those with heart failure with reduced ejection fraction (HFrEF), leaving a significant unmet need in the chronic heart failure market.

Finally, the underdiagnosis and delayed diagnosis of chronic heart failure in its early stages also poses a major challenge. Many patients may not experience noticeable symptoms until the disease is advanced, leading to poor prognosis and reduced effectiveness of interventions. Early identification and management of chronic heart failure are critical, but the lack of awareness and insufficient screening programs in some regions contribute to late-stage diagnoses.

These challenges underscore the need for continued innovation, improved accessibility, and early detection strategies to overcome the barriers to effective chronic heart failure management.

The global chronic heart failure market is highly competitive, with several key players driving innovation and market growth. Leading companies such as AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer AG, Eli Lilly and Company, and scPharmaceuticals are at the forefront of the market, each contributing through innovative therapies, medical devices, and treatments. These companies are focusing on expanding the availability of advanced drug therapies such as SGLT2 inhibitors (e.g., dapagliflozin), neprilysin inhibitors (e.g., sacubitril/valsartan), and ARBs, all of which are transforming the treatment of heart failure. Additionally, advancements in medical devices for heart failure management, such as implantable defibrillators and ventricular assist devices, are contributing to better patient outcomes. As these companies continue to invest in research and development, the competition within the chronic heart failure market is driving further innovation, ultimately leading to more effective treatments, improved patient quality of life, and reduced hospitalizations.

Chronic Heart Failure Market Segmentation:

Chronic Heart Failure Segmentation 1: by Region
• North America
• Europe
• Asia-Pacific

The global chronic heart failure market is experiencing significant transformation driven by several emerging trends. There is a growing emphasis on personalized medicine, with advancements in genomic testing and biomarker identification allowing for more tailored treatments that are specific to the patient’s unique condition, improving the effectiveness of therapies. Additionally, innovative drug therapies such as SGLT2 inhibitors, neprilysin inhibitors, and ARBs are gaining prominence for their ability to not only improve heart function but also reduce hospitalizations and enhance survival rates, particularly in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Another major trend is the increasing integration of digital health technologies such as wearables, remote monitoring devices, and telemedicine, which enable continuous tracking of patient health and more proactive management of chronic heart failure symptoms. These technologies help detect early signs of deterioration, prevent hospital readmissions, and optimize treatment regimens. Furthermore, the growing focus on patient-centred care is reshaping the chronic heart failure market by promoting a holistic approach to chronic heart failure management, combining pharmacological treatments with lifestyle modifications, rehabilitation, and psychological support to improve the quality of life for patients.

ページTOPに戻る

Table of Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. Global Chronic Heart Failure Market: Industry Outlook
1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Epidemiology Analysis
1.5 Clinical Trial Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities
2. Global Chronic Heart Failure Market (Region), ($Billion), 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Chronic Heart Failure Market, by Country
2.1.3.1.1 U.S.
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Chronic Heart Failure Market, by Country
2.2.3.1.1 Germany
2.2.3.1.2 U.K.
2.2.3.1.3 France
2.2.3.1.4 Italy
2.3 Asia Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia Pacific Chronic Heart Failure Market, by Country
2.3.3.1.1 China
2.3.3.1.2 Japan
3. Global Chronic Heart Failure Market: Competitive Landscape and Company Profiles
3.1 Key Strategies and Development
3.1.1 Mergers and Acquisitions
3.1.2 Synergistic Activities
3.1.3 Business Expansions and Funding
3.1.4 Product Launches and Approvals
3.1.5 Other Activities
3.2 Company Profiles
3.2.1 AstraZeneca
3.2.1.1 Overview
3.2.1.2 Top Products / Product Portfolio
3.2.1.3 Top Competitors
3.2.1.4 Target Customers/End-Users
3.2.1.5 Key Personnel
3.2.1.6 Analyst View
3.2.2 Bristol Myers Squibb
3.2.2.1 Overview
3.2.2.2 Top Products / Product Portfolio
3.2.2.3 Top Competitors
3.2.2.4 Target Customers/End-Users
3.2.2.5 Key Personnel
3.2.2.6 Analyst View
3.2.3 Cytokinetics
3.2.3.1 Overview
3.2.3.2 Top Products / Product Portfolio
3.2.3.3 Top Competitors
3.2.3.4 Target Customers/End-Users
3.2.3.5 Key Personnel
3.2.3.6 Analyst View
3.2.4 Bayer AG
3.2.4.1 Overview
3.2.4.2 Top Products / Product Portfolio
3.2.4.3 Top Competitors
3.2.4.4 Target Customers/End-Users
3.2.4.5 Key Personnel
3.2.4.6 Analyst View
3.2.5 Eli Lilly and Company
3.2.5.1 Overview
3.2.5.2 Top Products / Product Portfolio
3.2.5.3 Top Competitors
3.2.5.4 Target Customers/End-Users
3.2.5.5 Key Personnel
3.2.5.6 Analyst View
3.2.6 Novartis AG
3.2.6.1 Overview
3.2.6.2 Top Products / Product Portfolio
3.2.6.3 Top Competitors
3.2.6.4 Target Customers/End-Users
3.2.6.5 Key Personnel
3.2.7 Pfizer Inc.
3.2.7.1 Overview
3.2.7.2 Top Products / Product Portfolio
3.2.7.3 Top Competitors
3.2.7.4 Target Customers/End-Users
3.2.7.5 Key Personnel
3.2.7.6 Analyst View
3.2.8 Johnson & Johnson
3.2.8.1 Overview
3.2.8.2 Top Products / Product Portfolio
3.2.8.3 Top Competitors
3.2.8.4 Target Customers/End-Users
3.2.8.5 Key Personnel
3.2.8.6 Analyst View
3.2.9 Amgen Inc.
3.2.9.1 Overview
3.2.9.2 Top Products / Product Portfolio
3.2.9.3 Top Competitors
3.2.9.4 Target Customers/End-Users
3.2.9.5 Key Personnel
3.2.9.6 Analyst View
3.2.10 Takeda Pharmaceutical Company
3.2.10.1 Overview
3.2.10.2 Top Products / Product Portfolio
3.2.10.3 Top Competitors
3.2.10.4 Target Customers/End-Users
3.2.10.5 Key Personnel
3.2.10.6 Analyst View
3.2.11 AbbVie Inc.
3.2.11.1 Overview
3.2.11.2 Top Products / Product Portfolio
3.2.11.3 Top Competitors
3.2.11.4 Target Customers/End-Users
3.2.11.5 Key Personnel
3.2.11.6 Analyst View
3.2.12 Sanofi
3.2.12.1 Overview
3.2.12.2 Top Products / Product Portfolio
3.2.12.3 Top Competitors
3.2.12.4 Target Customers/End-Users
3.2.12.5 Key Personnel
3.2.12.6 Analyst View
4. Research Methodology
List of Figures
Figure Global Chronic Heart Failure Market (by Region), $Billion, 2024 and 2035
Figure Global Chronic Heart Failure Market Key Trends, Analysis
List of Tables
Table Global Chronic Heart Failure Market Dynamics, Impact Analysis
Table Global Chronic Heart Failure Market (by Region), $Billion, 2024-2035

Press Release